02196 復星醫藥
按盘价 
14.000 +0.140 (+1.010%) 盈利能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 资产回报率 (%) | 2.400% | 2.175% | 3.730% | 5.347% | 4.587% |
| 股东资金回报率 (%) | 5.965% | 5.320% | 8.933% | 12.431% | 10.652% |
| 资本运用回报率 (%) | 3.464% | 3.011% | 5.063% | 7.397% | 6.234% |
边际利润分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 毛利率 (%) | 47.774% | 47.646% | 47.115% | 47.947% | 54.469% |
| 未计利息、税项、折旧及摊销前利润率 (%) | 16.512% | 12.742% | 13.519% | 17.473% | 18.257% |
| 税前边际利润率 (%) | 10.191% | 7.944% | 10.455% | 15.548% | 15.508% |
| 纯利率 (%) | 6.771% | 5.815% | 8.530% | 12.167% | 12.143% |
变现能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 流动比率 (X) | 0.921 X | 1.001 X | 1.059 X | 1.038 X | 1.009 X |
| 速动比率 (X) | 0.727 X | 0.778 X | 0.853 X | 0.851 X | 0.801 X |
财务杠杆分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 总负债 / 总资产比率 (%) | 48.991% | 50.121% | 49.532% | 48.179% | 45.082% |
| 总债项 / 总资产比率 (%) | 30.613% | 30.845% | 28.064% | 27.157% | 28.861% |
| 净债项 / 总资产比率 (%) | 19.096% | 18.773% | 12.901% | 16.093% | 16.949% |
| 总债项 / 股东资金比率 (%) | 76.121% | 76.650% | 67.502% | 64.702% | 65.341% |
| 长期债项 / 股东资金比率 (%) | 27.498% | 34.076% | 28.844% | 24.777% | 24.644% |
| 净债项 / 股东资金比率 (%) | 47.483% | 46.650% | 31.031% | 38.341% | 38.373% |
| 净现金 / (债项) ($) | (224.23亿) | (212.94亿) | (138.18亿) | (150.06亿) | (141.74亿) |
| 每股净现金 / (债项) ($) | (8.436) | (7.968) | (5.171) | (5.855) | (5.531) |
| 总债项 / 资本运用比率 (%) | 44.950% | 43.914% | 40.723% | 39.611% | 41.078% |
| 利息盈利率 (X) | 3.912 X | 3.473 X | 5.753 X | 8.346 X | 6.310 X |
营运效率分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 存货周转率日数 (日) | 126.388日 | 121.864日 | 97.316日 | 95.945日 | 120.971日 |
| 应收贸易帐周转率日数 (日) | 70.005日 | 67.610日 | 56.897日 | 50.964日 | 56.963日 |
| 应付贸易帐周转率日数 (日) | 54.233日 | 55.056日 | 47.270日 | 39.223日 | 34.405日 |
| 备注： | 实时报价更新时间为16/05/2025 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | RMB 2,769,886 |
| 增长率 | 15.479% |
| 每股盈利/(亏损) | RMB 1.040 |
| 每股账面资产净值 (¥) | RMB 17.766 |